Supplementary Table 1, Figures 1 - 3 from A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T

Authors:
  • DMDouglas G. McNeel
    Douglas G. McNeel
  • TGThomas A. Gardner
    Thomas A. Gardner
  • CHCelestia S. Higano
    Celestia S. Higano
  • PKPhilip W. Kantoff
    Philip W. Kantoff
  • ESEric J. Small
    Eric J. Small
  • MWMark H. Wener
    Mark H. Wener
  • RSRobert B. Sims
    Robert B. Sims
  • TDTodd DeVries
    Todd DeVries
  • NSNadeem A. Sheikh
    Nadeem A. Sheikh
  • RDRobert Dreicer
    Robert Dreicer

Abstract
Supplementary Table S1. Baseline demographics and disease characteristics in patients with mCRPC from the phase III sipuleucel-T trials included in the eosinophil analysis and the overall pooled population. Supplementary Figure S1. Overview of the study designs of three phase III clinical trials from which data were pooled for this retrospective analysis. Supplementary Figure S2. Changes in eosinophil counts for sipuleucel-T-treated patients with or without an elevated eosinophil count in randomized phase III trials, versus the control group. Supplementary Figure S3. Association of immune response with change in eosinophil counts for sipuleucel-T-treated patients in randomized phase III trials.